Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Phase 3

Completed

Conditions: Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer
Bladder Cancer

First Posted Date: 2004-04-09

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 330

Registration Number: NCT00003376

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 47 locations

Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-08

Last Posted Date: 2015-11-17

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00081302

Locations: 🇺🇸
Arlington Cancer Center - Arlington, Arlington, Texas, United States

Combination Chemotherapy for Patients With Brain Cancer

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-04-06

Last Posted Date: 2011-10-27

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 20

Registration Number: NCT00002814

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-04-05

Last Posted Date: 2013-04-08

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00014573

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Phase 1

Conditions: Head and Neck Cancer

First Posted Date: 2004-03-31

Last Posted Date: 2013-09-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004097

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Lymphoma
Leukemia

First Posted Date: 2004-03-31

Last Posted Date: 2019-10-17

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 35

Registration Number: NCT00003402

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2004-03-22

Last Posted Date: 2008-07-24

Lead Sponsor: Theradex

Target Recruit Count: 60

Registration Number: NCT00003327

Locations: 🇺🇸
California Cancer Center, Fresno, California, United States
🇺🇸
Memorial Regional Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States

and more 17 locations

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-03-16

Last Posted Date: 2009-03-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004865

Locations: 🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States
🇺🇸
Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸
Cooper Cancer Institute, Camden, New Jersey, United States

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-03-16

Last Posted Date: 2013-08-20

Lead Sponsor: Genentech, Inc.

Registration Number: NCT00005635

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-03-15

Last Posted Date: 2013-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003742

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy